SCHEMBL4566706

SCHEMBL4566706

O=C(O)CC1C=CC=C2C1=Nc1ccccc12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7702661 0.77
SCHEMBL28285476 0.77 TTK (0.30)
SCHEMBL1120334 0.75 DRD2 (0.32)
SCHEMBL4098083 0.74 HTR2B (0.31)
SCHEMBL5881053 0.74 CYP19A1 (0.35)
SCHEMBL28102667 0.72 IDO1 (0.31)
SCHEMBL3976323 0.71
SCHEMBL28253806 0.71
SCHEMBL3979369 0.68
SCHEMBL4303456 0.68 KDM4E (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0310179-A2 Tetrahydrocarbazole esters MERCK FROSST CANADA INC. (CA) 1989-04-05 EP claimed
EP-2134169-A2 COMBINATION OF METFORMIN R-(+) LIPOATE AND ANTIHYPERLIPIDEMIC AGENTS FOR THE TREATMENT OF DIABETIC HYPERGLYCEMIA AND DIABETIC COMPLICATIONS Indigene Pharmaceuticals Inc. (US) 2009-12-23 EP disclosed
WO-2008112166-A2 COMBINATION OF METFORMIN R-(+) LIPOATE AND ANTIHYPERLIPIDEMIC AGENTS FOR THE TREATMENT OF DIABETIC HYPERGLYCEMIA AND DIABETIC COMPLICATIONS INDIGENE PHARMACEUTICALS INC. (US) 2008-09-18 WO disclosed